The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the major causes of mortality. ABT-263 is a newly synthesized, orally available Bcl-2/xL inhibitor that shows promising efficacy in HCC therapy. ABT-263 inhibits the anti-apoptotic activity of Bcl-2 and Bcl-xL, but not Mcl-1. Previous reports have...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bin, Ni, Zhenhong, Dai, Xufang, Qin, Liyan, Li, Xinzhe, Xu, Liang, Lian, Jiqin, He, Fengtian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021276/
https://www.ncbi.nlm.nih.gov/pubmed/24779770
http://dx.doi.org/10.1186/1476-4598-13-98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021276/
https://www.ncbi.nlm.nih.gov/pubmed/24779770
http://dx.doi.org/10.1186/1476-4598-13-98

Ejemplares similares